Optimized Preload Leakage-Correction Methods to Improve the Diagnostic Accuracy of Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging in Posttreatment Gliomas

References

1. 1.↵
   1. Sugahara T,
   2. Korogi Y,
   3. Tomiguchi S,
   4. et al

   . Post-therapeutic intra-axial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol 2000; 21: 901–09

   Abstract/FREE Full Text
2. 2.↵
   1. Hu LS,
   2. Baxter LC,
   3. Smith KA,
   4. et al

   . Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol 2009; 30: 552–58

   Abstract/FREE Full Text
3. 3.↵
   1. Paulson ES,
   2. Schmainda KM

   . Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. Radiology 2008; 249: 601–13

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Boxerman JL,
   2. Schmainda KM,
   3. Weisskoff RM

   . Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 2006; 27: 859–67

   Abstract/FREE Full Text
5. 5.↵
   1. Kassner A,
   2. Annesley DJ,
   3. Zhu XP,
   4. et al

   . Abnormalities of the contrast re-circulation phase in cerebral tumors demonstrated using dynamic susceptibility contrast-enhanced imaging: a possible marker of vascular tortuosity. J Magn Reson Imaging 2000; 11: 103–13

   CrossRefPubMed
6. 6.↵
   1. Lev MH,
   2. Ozsunar Y,
   3. Henson JW,
   4. et al

   . Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol 2004; 25: 214–21

   Abstract/FREE Full Text
7. 7.↵
   1. Johnson G,
   2. Wetzel SG,
   3. Cha S,
   4. et al

   . Measuring blood volume and vascular transfer constant from dynamic, T(2)*-weighted contrast-enhanced MRI. Magn Reson Med 2004; 51: 961–68

   CrossRefPubMed
8. 8.↵
   1. Bruening R,
   2. Kwong KK,
   3. Vevea MR,
   4. et al

   . Echo-planar MR determination of relative cerebral blood volume in human brain tumors: T1 versus T2 weighting. AJNR Am J Neuroradiol 1996; 17: 831–40

   Abstract
9. 9.↵
   1. Sugahara T,
   2. Korogi Y,
   3. Kochi M,
   4. et al

   . Perfusion-sensitive MR imaging of gliomas: comparison between gradient-echo and spin-echo echo-planar imaging techniques. AJNR Am J Neuroradiol 2001; 22: 1306–15

   Abstract/FREE Full Text
10. 10.↵
    1. Sorensen AG

    . Perfusion MR imaging: moving forward. Radiology 2008; 249: 416–17

    CrossRefPubMed
11. 11.↵
    1. Juluru K,
    2. Vogel-Claussen J,
    3. Macura KJ,
    4. et al

    . MR imaging in patients at risk for developing nephrogenic systemic fibrosis: protocols, practices, and imaging techniques to maximize patient safety. Radiographics 2009; 29: 9–22

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Hu LS,
    2. Baxter LC,
    3. Paine TL

    . Leakage corrected rCBV measurements using prebolus dosing: applications in differentiating glioma recurrence from post-treatment effect at 3T field strength. In: Proceedings of the International Society for Magnetic Resonance in Medicine, Toronto, Ontario, Canada. May 3–9, 2008
13. 13.↵
    1. Donahue KM,
    2. Krouwer HG,
    3. Rand SD,
    4. et al

    . Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphology maps in brain tumor patients. Magn Reson Med 2000; 43: 845–53

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Rosen BR,
    2. Belliveau JW,
    3. Vevea JM,
    4. et al

    . Perfusion imaging with NMR contrast agents. Magn Reson Med 1990; 14: 249–65

    PubMedWeb of Science
15. 15.↵
    1. Boxerman JL,
    2. Hamberg LM,
    3. Rosen BR,
    4. et al

    . MR contrast due to intravascular magnetic susceptibility perturbations. Magn Reson Med 1995; 34: 555–66

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Perkiö J,
    2. Aronen HJ,
    3. Kangasmäki A,
    4. et al

    . Evaluation of four postprocessing methods for determination of cerebral blood volume and mean transit time by dynamic susceptibility contrast imaging. Magn Reson Med 2002; 47: 973–81

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Sadeghi N,
    2. Salmon I,
    3. Decaestecker C,
    4. et al

    . Stereotactic comparison among cerebral blood volume, methionine uptake, and histopathology in brain glioma. AJNR Am J Neuroradiol 2007; 28: 455–61

    Abstract/FREE Full Text
18. 18.↵
    1. Uematsu H,
    2. Maeda M

    . Double-echo perfusion-weighted MR imaging: basic concepts and application in brain tumors for the assessment of tumor blood volume and vascular permeability. Eur Radiol 2006; 16: 180–06

    CrossRefPubMed
19. 19.↵
    1. Roberts HC,
    2. Roberts TP,
    3. Brasch RC,
    4. et al

    . Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol 2000; 21: 891–99

    Abstract/FREE Full Text
20. 20.↵
    1. Manka C,
    2. Träber F,
    3. Gieseke J,
    4. et al

    . Three-dimensional dynamic susceptibility-weighted perfusion MR imaging at 3.0 T: feasibility and contrast agent dose. Radiology 2005; 234: 869–77

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Wedeking P,
    2. Eaton S,
    3. Covell DG,
    4. et al

    . Pharmacokinetic analysis of blood distribution of intravenously administered 153Gd-labeled Gd(DTPA)2- and 99mTc(DTPA) in rats. Magn Reson Imaging 1990; 8: 567–75

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Poetker DM,
    2. Jursinic PA,
    3. Runge-Samuelson CL,
    4. et al

    . Distortion of magnetic resonance images used in gamma knife radiosurgery treatment planning: implications for acoustic neuroma outcomes. Otol Neurotol 2005; 26: 1220–28

    CrossRefPubMed
23. 23.↵
    1. Stadlbauer A,
    2. Ganslandt O,
    3. Buslei R,
    4. et al

    . Gliomas: histopathologic evaluation of changes in directionality and magnitude of water diffusion at diffusion-tensor MR imaging. Radiology 2006; 240: 803–10

    CrossRefPubMed
24. 24.↵
    1. Brandsma D,
    2. Stalpers L,
    3. Taal W,
    4. et al

    . Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008; 9: 453–61

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Perry A,
    2. Schmidt RE

    . Cancer therapy-associated CNS neuropathology: an update and review of the literature. Acta Neuropathol 2006; 111: 197–212

    CrossRefPubMed